Lhcl.Cm
LHCL.CM operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
Business. LHCL.CM operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
LHCL.CM operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
LHCL.CM maintains a strong liquidity position, with a current ratio of 4.13, indicating the company has sufficient current assets to cover its current liabilities multiple times over. The company's liquidity_fpt score further supports this, showing a low liquidity risk. Additionally, the company has a significant amount of cash and equivalents, amounting to 1,182,441,070 LKR, which provides a buffer against short-term financial obligations.
In terms of profitability, LHCL.CM demonstrates a return on equity (ROE) of 12.66% and a return on assets (ROA) of 9.54%, both of which are strong indicators of the company's ability to generate profits from its equity and assets. These figures suggest that the company is effectively utilizing its resources to generate returns, which is in line with the preferred metrics for the healthcare industry.
The company's revenue is primarily concentrated in its pharmaceutical segment, with no significant geographic diversification disclosed in the available data. This concentration may pose a risk if the pharmaceutical market experiences a downturn or if regulatory changes impact the segment.
Looking at the growth trajectory, LHCL.CM has shown consistent revenue and net income growth. The company's recent financial performance indicates a positive outlook for the current fiscal year, with the potential for continued growth in the next fiscal year. The capital expenditure of -908,192,670 LKR suggests that the company is investing in its operations, which could support future growth.
The risk assessment for LHCL.CM indicates a low risk of dilution and no immediate filing-based liquidity or dilution flags. The company's debt to equity ratio of 0.04 is relatively low, suggesting that it is not heavily leveraged and has a strong equity position. This low leverage reduces the risk of financial distress and provides flexibility for future investments.
Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's last actual EPS was 2.48 LKR, and its last actual revenue was 6,382,058,010 LKR, both of which are positive indicators of its financial health.
- LHCL.CM has a strong liquidity position with a current ratio of 4.13 and significant cash reserves.
- The company demonstrates strong profitability with a ROE of 12.66% and a ROA of 9.54%.
- Revenue is primarily concentrated in the pharmaceutical segment, which may pose a risk if the market experiences a downturn.
- The company has a low debt to equity ratio of 0.04, indicating a strong equity position and low leverage.
- No immediate liquidity or dilution risks were detected, and the company has a positive outlook for continued growth.
- **margin_outlook_rationale**: The company's strong gross profit margin and operating margin suggest a positive outlook for maintaining profitability.
- **rd_outlook_rationale**: The company's investment in capital expenditures indicates a commitment to future growth and innovation.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- LHCL.CM Market data — financials · 2026-05-28
- Lanka Hospitals Corporation PLC Market data — analyst estimates · 2026-05-28